Immunome, Inc. IMNM
19.07 USD +0.42 (+2.25%)
At closeNov 11, 2026, 4:01 PM EST
19.07 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
18.71 Day range 19.29
16.11 52-week range 30.06
- YTD
- -11.22%
- 1 year
- +8.85%
- Market cap
- 2.25B
- EPS (ttm)
- -2.63
- Shares out
- 118.07M
- Forward P/E
- -7.48
- YTD return
- -11.22%
- 1-year return
- +8.85%
- Volume
- 872.89K
- Avg volume
- 1.38M
- Open
- 18.81
- Previous close
- 18.65
- Day's range
- 18.71 – 19.29
- 52-week range
- 16.11 – 30.06
- Beta
- 2.66
- Analysts
- Strong Buy
- Price target
- 35.20 (+84.6%)
- Earnings date
- Mar 2, 2027
5D +0.13 (+0.68%)
Key statistics
- Enterprise value
- 1.75B
- PEG ratio
- 0.00
- Price / book
- 4.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -159.73M
- Total cash
- 461.58M
- Total debt
- 11.38M
- Return on equity
- -78.71%
- Short % of float
- 15.92%
- 50-day average
- 21.15
- 200-day average
- 22.31
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.20 +84.6% upside
Now 19.07
- Target (low)
- 24.00
- Target (mean)
- 35.20
- Target (high)
- 40.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 2, 2027
Expected Mar 2, 2027. Consensus EPS estimate -0.71775.
Financials — quick view
IMNM Revenue — quarterly 0
IMNM Net income — quarterly -85.78M
IMNM EPS — quarterly -0.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 2, 2027 | Dec 30, 2026 | -0.68 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.62174 | -0.76 | -0.14 | -22.24% |
| Aug 11, 2026 | Jun 30, 2026 | -0.51381 | -0.65 | -0.14 | -26.51% |
| May 12, 2026 | Mar 31, 2026 | -0.60 | -0.48 | +0.12 | +20.00% |
| Mar 3, 2026 | Dec 31, 2025 | -0.59017 | -0.75 | -0.16 | -27.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Stifel | main | Hold | Hold |
| Nov 10, 2026 | Piper Sandler | main | Overweight | Overweight |
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 1, 2026 | Stifel | init | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | init | — | Buy |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunome.com
News
Immunome Analysts Cut Their Forecasts After Q3 Results 
Immunome Analysts Cut Their Forecasts After Q3 Results 
Stifel Maintains Hold on Immunome, Lowers Price Target to $23 
Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30 
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update 
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know 
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors 
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target
Your note
Sign in to keep a note on IMNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARCHAS ISAAC | Director | Sale | Aug 11, 2026 | 0 |
| BIENAIME JEAN-JACQUES | Director | Purchase | Jun 4, 2026 | 43,415 |
| HIGGINS JACK | Officer | Conversion of Exercise of derivative security | Sep 10, 2026 | 59,250 |
| HORN KINNEY | Officer | Conversion of Exercise of derivative security | Aug 3, 2026 | 0 |
| LECHLEIDER ROBERT | Officer | Stock Award(Grant) | Jul 22, 2026 | 69,805 |
| ROSETT MAX | Chief Financial Officer | Stock Award(Grant) | Jul 22, 2026 | 101,287 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.67% | 19,676,883 | 375.24M | Jun 29, 2026 |
| FMR, LLC | 14.43% | 17,036,641 | 324.89M | Sep 29, 2026 |
| Blackrock Inc. | 7.46% | 8,805,492 | 167.92M | Jun 29, 2026 |
| State Street Corporation | 4.65% | 5,494,625 | 104.78M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.41% | 5,210,216 | 99.36M | Jun 29, 2026 |
| Redmile Group, LLC | 4.16% | 4,911,590 | 93.66M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 6.08% | 7,179,563 | 136.91M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.24% | 5,004,684 | 95.44M | Sep 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.31% | 3,907,378 | 74.51M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.14% | 3,703,461 | 70.63M | Jul 30, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.13% | 3,692,941 | 70.42M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.87% | 3,392,151 | 64.69M | Jun 29, 2026 |